Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | TDO2 | P48775 | 2/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588409 | 1.00 | IDO1 (0.59) | IDO1TDO2ADRB2SCN4ADPP4 | |
| SCHEMBL588076 | 1.00 | IDO1 (0.59) | IDO1TDO2ADRB2SCN4ADPP4 | |
| Hydrochloric Acid SCHEMBL1143208 | 0.98 | IDO1 (0.61) | IDO1TDO2ADRB2SCN4ADPP4 | |
| Hydrochloric Acid SCHEMBL3998446 | 0.95 | IDO1 (0.55) | IDO1TDO2ADRB2SCN4ADPP4 | |
| SCHEMBL1732927 | 0.89 | ADRB2 (0.62) | IDO1TDO2ADRB2TSHRHIF1A | |
| Hydrochloric Acid SCHEMBL3179658 | 0.87 | ADRB2 (0.59) | IDO1TDO2ADRB2TSHRHIF1A | |
| SCHEMBL11480062 | 0.87 | DPP4 (0.61) | DPP4F2TSHRHIF1AADRA2A | |
| SCHEMBL11478580 | 0.87 | DPP4 (0.61) | DPP4F2TSHRHIF1AADRA2A | |
| Aminodiphenylmethane SCHEMBL7841 | 0.84 | DPP4 (0.65) | DPP4F2TSHRHIF1AADRA2A | |
| Aminodiphenylmethane SCHEMBL7719817 | 0.81 | DPP4 (0.55) | DPP4F2TSHRHIF1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573477-A | Resveratrol imine analogue and preparation method and application thereof | 西安医学院 | 2022-06-03 | — | — | CN | claimed |
| CN-107466322-B | Mutant transaminases and methods and uses related thereto | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | claimed |
| EP-3283622-B1 | MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO | HOFFMANN LA ROCHE (CH) | 2019-07-03 | — | — | EP | claimed |
| US-10017749-B2 | Mutant transaminases as well as methods and uses relating thereto | HOFFMAN-LA ROCHE INC. (US) | 2018-07-10 | — | — | US | claimed |
| EP-3283622-A1 | MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO | F. Hoffmann-La Roche AG (CH) | 2018-02-21 | — | — | EP | claimed |
| WO-2016166120-A1 | MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-20 | — | — | WO | claimed |
| US-20160304843-A1 | MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO | HOFFMANN-LA ROCHE INC. (US) | 2016-10-20 | — | — | US | claimed |
| EP-2167479-B1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LTD (IN) | 2013-09-11 | — | — | EP | claimed |
| WO-2012101475-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ANTIHISTAMINIC DRUGS VIA A NOVEL CARBAMATE INTERMEDIATE | JUBILANT LIFE SCIENCES LIMITED (IN) | 2012-08-02 | — | — | WO | claimed |
| US-8084606-B2 | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates | SYMED LABS LIMITED (IN) | 2011-12-27 | — | — | US | claimed |
| EP-1869038-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-07-08 | — | — | EP | claimed |
| WO-2009062036-A2 | PROCESSES FOR PREPARING LEVOCETIRIZINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | claimed |
| CN-101356162-A | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-01-28 | — | — | CN | claimed |
| WO-2008152650-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY OPTICALLY PURE LEVOROTATORY AND DEXTROROTATORY ENANTIOMERS OF CETIRIZINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2008-12-18 | — | — | WO | claimed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | claimed |
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2004-06-24 | — | — | US | claimed |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | COSSEMENT ERIC (BE) | 2003-10-30 | — | — | US | claimed |
| EP-0617028-B1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl] piperazine | UCB SA (BE) | 2000-06-14 | — | — | EP | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122021-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl)-4-[(4-methylphenyl)sulfonyl) piperazine | RPLP1, QDPR, RPLP2 | IDO1 1619/4885TDO2 1039/4885ADRB2 47/4885 |
| US-20030204089-A1 | Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | IDO1 1623/4885TDO2 1065/4885ADRB2 43/4885 |
| US-10017749-B2 | Mutant transaminases as well as methods and uses relating thereto | GOT1, GOT2, OAT | IDO1 2020/4885TDO2 327/4885ADRB2 4605/4885 |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | CYP3A7, CYP3A5, CYP2D6 | IDO1 472/4885TDO2 946/4885ADRB2 59/4885 |
| US-20040122023-A1 | Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine | RPLP1, QDPR, PRLHR | IDO1 1623/4885TDO2 1065/4885ADRB2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.